GSK GlaxoSmithKline PLC

39.85
-0.13  -0%
Previous Close 39.98
Open 39.94
Price To Book 17.48
Market Cap 99378789325
Shares 2,493,821,564
Volume 2,670,235
Short Ratio 3.89
Av. Daily Volume 2,504,265

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
TSR-042
First-line ovarian cancer
FDA Approval announced July 23, 2018.
Tafenoquine
Malaria
Approval announced April 24, 2018 for expanded label.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approval announced December 12, 2017.
Mepolizumab
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Phase 1/2 data due 1H 2019.
Niraparib - AVANOVA
Ovarian cancer
Phase 3 data due 2H 2020.
Mepolizumab
Severe hypereosinophilic syndrome (HES)
Phase 1/2 trial ongoing. Data at ASCO 2018 noted ORR 25%.
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Approval announced January 11, 2018.
Fluarix Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 3 data due 2H 2019.
Niraparib - PRIMA
First-line ovarian cancer
Approval announced September 18, 2017.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
Approval announced November 21, 2017.
Dolutegravir + rilpivirine
HIV
Advisory Committee July 25, 2018 voted 3-16 against recommending approval. CRL issued September 7, 2018.
Mepolizumab
Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype
FDA approval announced April 8, 2019.
Dolutegravir + lamivudine
HIV
Phase 3 data due 2H 2020.
Daprodustat - ASCEND-D
Anemia
Phase 3 data due 2H 2020.
Cabotegravir
HIV
Development discontinued due to lack of efficacy.
Danirixin
Chronic obstructive pulmonary disease (COPD)
Approval announced October 20, 2017.
Shingrix
Shingles
Approval announced July 21, 2017.
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)
Phase 3 data due 1H 2019.
Closed Triple - CAPTAIN
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD
CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 3 trial no longer be expected to serve as a registration trial - noted March 27, 2017.
Niraparib - BRAVO
Cancer - breast
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
Phase 2 top-line data released April 24, 2018. Primary endpoint met. sNDA to be potentially filed 2H 2018.
Niraparib - (QUADRA trial)
Cancer - ovarian
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
BLA filing due YE 2019.
TSR-042 - GARNET
Endometrial cancer
Phase 3 data positive data released October 30, 2018.
Dolutegravir + rilpivirine
Injectable 2DR in HIV
Phase 2 additional data due 1H 2019.
Niraparib - JASPER
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2020.
Benlysta (belimumab) and rituximab
Systemic lupus erythematosus (SLE)
Phase 2b released October 21, 2018 did not meet primary endpoint.
MOR103/GSK3196165
Rheumatoid Arthritis
Phase 1 data at SITC Novemeber 2018 - 15% ORR for high dose , 9% ORR for lower dose.
TSR-022 + TSR-042 AMBER
Solid tumors
Phase 2 data due late-2019.
Niraparib + bevacizumab OVARIO
Ovarian cancer
Phase 1 trial ongoing.
TSR-033 - CITRINO
Solid tumors
Phase 3 data due 1H 2020.
Mepolizumab - SYNAPSE
Nasal polyps
Phase 3 data due 2H 2019.
GSK’916 (BCMA)
Multiple myeloma
sBLA filing announced November 19, 2018.
Mepolizumab
Severe eosinophilic asthma - pediatric
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer